Transformation post-Zubsolv sale led to one-time costs and high cash burn, but R&D pipeline progress continues with Izipry and OX640 nearing key milestones. DOJ settlement discussions are advancing, and business development is focused on AmorphOX partnerships and securing commercial partners for late-stage assets.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.